Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease
Objective: This case report aims to highlight the impact of increasing venlafaxine dose on the worsening of dyskinesias and the onset of ocular dyskinesia³ and…Amitriptyline-Induced Rabbit Syndrome: A Case of Refractory Oral Vertical Dyskinesia
Objective: We present a case of refractory rabbit syndrome associated with the use of amitriptyline, a tricyclic antidepressant, highlighting both the diagnostic and therapeutic challenges…Comparison of Age, Cognitive, Autonomic, and Motor Testing between Serotonergic vs Idiopathic REM-Sleep Behavior Disorder
Objective: To compare the age, cognitive, autonomic, and motor function of REM-Sleep Behavior Disorder (RBD) patients amongst those who believe their symptoms were triggered by…Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder
Objective: This investigation delineates the pharmacokinetic intricacies encountered in the therapeutic management of a geriatric patient with Parkinson’s Disease (PD) concomitantly suffering from refractory Major…Acute dystonic dyskinesias in a patient used fluvoxamine. Case report
Objective: To represent a case of acute dystonic dyskinesias after fluvoxamine use by the patient with obsessive thoughts and movements. Background: In psychiatric clinical practice,…Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report
Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…Improving Neuropsychiatric Comorbidity in Geriatric Spinocerebellar Ataxia
Objective: This study evaluates neuropsychiatric comorbidity in spinocerebellar ataxia (SCA) and highlights key aspects of management in the geriatric population. It discusses efficacy of neuropsychotropic…The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative
Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Clinical features and phenoconversion risk in women with isolated REM sleep behavior disorder
Objective: To determine features predictive of differential phenoconversion rates in isolated REM sleep Behavior Disorder (iRBD) to a defined neurodegenerative disease (NDD). Background: iRBD is…
- 1
- 2
- 3
- 4
- Next Page »